Penn State College of Medicine

Penn State Health Milton S. Hershey Medical Center joins global clinical trial evaluating antiviral drug remdesivir for treatment of COVID-19

Study enrolls first patients in COVID-19 clinical trial using a drug previously developed to treat Ebola

Newswise — Penn State Health Milton S. Hershey Medical Center has begun enrolling participants in an international clinical trial evaluating an investigational antiviral drug, remdesivir, for treatment of coronavirus disease 2019 (COVID-19). Remdesivir has been previously tested in humans with Ebola virus disease and has shown some therapeutic benefit against SARS and MERS coronaviruses in animal models.

There are no specific therapeutics approved by the U.S. Food and Drug Administration to treat people with COVID-19, which has sickened almost 2 million people and caused more than 124,000 deaths worldwide as of April 14. The trial will assess the safety and efficacy of remdesivir in hospitalized patients with moderate-to-severe COVID-19.

“Health care providers around the world are looking for effective therapies to treat COVID-19,” said Dr. Catharine Paules, an infectious disease physician with Penn State Health. “This clinical trial provides us with an opportunity to begin investigating whether this experimental therapy may be safe and helpful to patients in our community and beyond.”

Remdesivir was developed by Gilead Sciences, Inc., and is not approved anywhere globally for use outside of clinical trials. Preclinical data on remdesivir in MERS and SARS coronaviruses – which are similar to SARS-CoV-2, the virus that causes COVID-19 – indicate that remdesivir may have potential activity against COVID-19.

“We urgently need treatment options for COVID-19 as we continue to battle this virus,” Paules said. “We thank the trial participants who are helping contribute to the discovery of new therapies, which is a core part of why Penn State Health and Penn State College of Medicine exist.”

The Milton S. Hershey Medical Center is one of 75 sites worldwide to participate in the trial, which is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. They are the only site to offer the trial in central Pennsylvania.

Enrollment at the Hershey Medical Center site is open only to patients hospitalized with COVID-19. The clinical trial is randomized, controlled and double blind, meaning medical professionals and patients won’t know whether patients receive remdesivir or placebo – a solution that contains inactive ingredients.The research team will reach out to eligible hospitalized patients directly.

Dr. Neal Thomas, associate dean for clinical research at Penn State College of Medicine, said the strong efforts of staff and faculty at the Clinical Trials Office and the Office of Research Affairs have allowed Penn State to join this effort to investigate new treatments for patients diagnosed with COVID-19.

“I’m proud of how hard our clinical research staff have worked to make this trial happen,” Thomas said. “Their efforts have increased the access patients in central Pennsylvania have to leading-edge treatments for many human illnesses, now including this novel coronavirus.”

For more information, visit ClinicalTrials.gov and search identifier NCT04280705

This research is supported by the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

 

About Penn State Health Milton S. Hershey Medical Center
Founded in 1963 through a gift from The Milton S. Hershey Foundation, Penn State Health Milton S. Hershey Medical Center is a leading academic medical center located in Hershey, Pa. The 548-bed Milton S. Hershey Medical Center is a provider of high-level, patient-focused medical care. Annually the Medical Center admits 29,000 patients, accepts over 1 million outpatient visits, receives 73,000 emergency room patients and performs 33,000 surgical procedures. As a Magnet-designated hospital since 2007, Hershey Medical Center employs caregivers who are dedicated to excellence and achieving superior patient and community outcomes. The Hershey Medical Center campus includes Penn State College of Medicine (Penn State’s medical school), Penn State Cancer Institute and Penn State Children’s Hospital—the region’s only children’s hospital.

 

About Penn State College of Medicine
Located on the campus of Penn State Health Milton S. Hershey Medical Center in Hershey, Pa., Penn State College of Medicine boasts a portfolio of nearly $100 million in funded research. Projects range from development of artificial organs and advanced diagnostics to groundbreaking cancer treatments and understanding the fundamental causes of disease. Enrolling its first students in 1967, the College of Medicine has more than 1,700 students and trainees in medicine, nursing, other health professions and biomedical research in both Hershey and State College, Pa.

 

About the National Institutes of Health remdesivir clinical trial offered at Penn State College of Medicine
Remdesivir is an investigational intravenous drug with broad antiviral activity. It is an experimental treatment and patient participation in this clinical investigation is optional. As with any medication, side effects are possible. Participants undergo baseline physical exams before receiving treatment and are monitored throughout the trial. Participants must have laboratory-confirmed SARS-CoV-2 infection with certain respiratory symptoms. Individuals with confirmed, mild infections with cold-like symptoms or no apparent symptoms will not be included in the study. In accordance with standard clinical research protocol, eligible patients will provide informed consent to participate in this trial. 




Filters close

Showing results

110 of 3409
Newswise: Last-resort life support option helped majority of critically ill COVID-19 patients survive, global study shows
24-Sep-2020 3:20 PM EDT
Last-resort life support option helped majority of critically ill COVID-19 patients survive, global study shows
Michigan Medicine - University of Michigan

It saved lives in past epidemics of lung-damaging viruses. Now, the life-support option known as ECMO appears to be doing the same for many of the critically ill COVID-19 patients who receive it. Patients in a new international study faced a staggeringly high risk of death, as ventilators failed to support their lungs. But after they were placed on ECMO, their actual death rate was less than 40%.

Released: 25-Sep-2020 5:05 PM EDT
Case Western Reserve University researchers to examine how COVID-19 ravaged America’s nursing homes
Case Western Reserve University

Within a few months, federal officials reported that one of every five nursing homes had experienced a death from the novel coronavirus. Not long after, several media outlets published independent analysis finding that an estimated 40% of the fatalities related to COVID-19 took place in nursing homes. Rather than surrender to the terrifying trend, Case Western Reserve researchers saw an opportunity to help.

Released: 25-Sep-2020 4:15 PM EDT
Faced with pandemic shortages, researchers combine heat and humidity to disinfect N95 masks for reuse
SLAC National Accelerator Laboratory

They found that gently heating N95 masks in high relative humidity could inactivate SARS-CoV-2 virus trapped within the masks, without degrading the masks’ performance.

Released: 25-Sep-2020 3:30 PM EDT
Team assessing if dual-antibody injection prevents COVID-19 illness
University of Texas Health Science Center at Houston

A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.

Released: 25-Sep-2020 2:30 PM EDT
Yes, Wisconsin Republicans have the power to overturn the extended mask mandate order by Governor Evers
Newswise

Republicans have the legal power to reverse the order by Wisconsin Governor Tony Evers that extends the mask mandate.

Released: 25-Sep-2020 1:55 PM EDT
How do Americans view the virus? Anthropology professor examines attitudes of COVID
Northern Arizona University

In her ongoing research about Americans' responses to the COVID-19 pandemic, Northern Arizona University anthropology professor Lisa Hardy and her collaborators have talked to dozens of people.

Released: 25-Sep-2020 12:55 PM EDT
During pandemic, racism puts additional stress on Asian Americans
Massachusetts General Hospital

Many people are feeling anxious during these uncertain times as they navigate the risks associated with COVID-19 and experience the tension from physical distancing or isolation for what can seem like an eternity.

Released: 25-Sep-2020 12:55 PM EDT
COVID-19 shapes political approval ratings
University of North Carolina at Chapel Hill

Approval ratings of political leaders surged in the early days of the COVID-19 pandemic, according to a new study published in the Proceedings of the National Academy of Sciences.

Released: 25-Sep-2020 12:40 PM EDT
ASU Researchers Receive $6m State Contract to Develop Rapid, 20-Minute Covid-19 Saliva Test
Arizona State University (ASU)

As the world manages through the coronavirus pandemic, Arizona State University continues its work to discover and develop easier and more widespread COVID-19 testing to assist in managing the virus.

Released: 25-Sep-2020 11:55 AM EDT
Scholars untangle marketing's complex role in understanding political activities
American Marketing Association (AMA)

As 2020 began, many pundits predicted a politically charged year, but few predicted that it would include a global pandemic overtaxing healthcare resources, strained U.S. race relations resulting in mass demonstrations across the globe, devastating fires consuming massive swaths of the United States, and a catastrophic global economic downturn.


Showing results

110 of 3409

close
1.49419